Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

XRN vs CHCT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CHCT Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

CHCT Overall Winner 6-Pillar Tally: XRN 0 – 5 CHCT (1 Tie) Matrix Metrics: XRN 1 – 9 CHCT

As of Nov 17, 2026, Community Healthcare Trust Incorporated (CHCT) is the stronger overall head-to-head candidate over XRN (XRN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XRN carries a Unified Composite Score of 45.3/100 (HOLD) at $25.79 (N/M Forward P/E, N/A operating margin), whereas CHCT carries 28.1/100 (SELL) at $14.52 (37.3x Forward P/E, 28.1% operating margin).

  • Composite vs. Pillar Nuance: While XRN currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. CHCT 28.1/100 SELL), CHCT captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (28.1% vs. N/A operating margin) and revenue trajectory (+4.4% vs. N/A YoY).
  • Technical & Structure Timing Caution: XRN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.5); meanwhile CHCT trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 58.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XRN vs CHCT
XRN US Equity
XRN
Institutional Equity
$25.79
-2.35% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.50β · 47% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 45.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.1%), weak momentum, RSI 28
RSI-14: 28.5 · SMA20: $28.74 · SMA50: $32.14
CHCT NYSE Head-to-Head Winner
Community Healthcare Trust Incorporated Common Stock, $0.01 par value per share
Real Estate Investment Trusts
$14.52
-1.49% 1D
Market Cap $422.8M
TTM Revenue $126M
Forward P/E 37.3x
Beta / 30D Vol 0.19β · 45% Vol
Unified Composite Score
28.1 / 100 SELL
Tech 8.0 Fund 34.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 58
RSI-14: 58.4 · SMA20: $13.86 · SMA50: $13.93

6-Pillar Scorecard Institutional Category Breakdown (XRN 0 – 5 CHCT)

Columns: Metric · XRN · CHCT
1. Valuation Multiples CHCT
Forward P/E N/M 37.3x
Trailing P/E N/M 20.1x
PEG Ratio N/M N/M
EV / Revenue N/M 3.4x
2. Growth & Scale CHCT
Revenue Growth (YoY) N/A +4.4%
Earnings Growth (YoY) N/A +179.9%
TTM Revenue (USD) N/A $126M
Market Cap N/A $422.8M
3. Profitability & Quality CHCT
Gross Margin N/A 80.8%
Operating Margin N/A 28.1%
Net Profit Margin N/A 17.8%
Return on Equity (ROE) N/A 5.3%
4. Balance Sheet & Cash Flow CHCT
Cash Generation (TTM) N/A $80M EBITDA
Cash Flow Margin N/A 63.2% EBITDA Mgn
Net Cash / Leverage N/A ROE $15.26 Book/Sh · 5.3% ROE
Dividend Yield None (0.00%) 11.24%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 38.6% (35th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CHCT
OpEx & R&D Intensity N/A 52.7% of Rev ($66M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Institutional Equity Operator REIT - Healthcare Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XRN (1) vs CHCT (9)
Institutional Metric XRN CHCT Criterion Row Edge
Market Capitalization
Scale
N/A $422.8M Larger Scale CHCT
Trailing P/E Ratio
Valuation
N/M 20.1x Lower Multiple CHCT
Forward P/E Ratio
Valuation
N/M 37.3x Lower Multiple CHCT
Revenue Growth (YoY)
Growth
N/A +4.4% Higher Growth CHCT
Operating Margin (TTM)
Profitability
N/A 28.1% Higher Margin CHCT
Net Profit Margin
Profitability
N/A 17.8% Higher Margin CHCT
Return on Equity (ROE)
Capital Efficiency
N/A 5.3% Higher ROE CHCT
52-Week Range Position
Momentum
1% ($26–$39) 30% ($13–$19) Stronger Trend CHCT
Beta / 30D Volatility
Risk Regime
0.50β · 47% Vol 0.19β · 45% Vol Lower Realized Risk CHCT
Unified Institutional Score
Composite Signal
45.3 / 100 (HOLD) 28.1 / 100 (SELL) Higher Composite XRN
Trailing 12M Revenue (USD)
Operating Scale
N/A $126M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 80.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $80M EBITDA ($15.26 Book/Sh · 5.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CHCT +26.64 pp
XRN: -13.02% · CHCT: +13.62%
3M Horizon CHCT +28.22 pp
XRN: -30.05% · CHCT: -1.83%
6M Horizon CHCT +8.64 pp
XRN: -24.9% · CHCT: -16.26%
1Y Horizon CHCT +17.08 pp
XRN: -28.16% · CHCT: -11.08%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XRN vs CHCT. Trailing 12-month operating profitability (XRN N/A vs CHCT 28.1%) and valuation multiples (XRN N/M vs CHCT 37.3x Forward P/E) are benchmarked directly in Pillar 4 below.

XRN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
CHCT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$126M
Gross Margin80.8%
Op. Margin28.1%
ROE / Fwd P/E5.3% · 37.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XRN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XRN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CHCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 38.6%
IV Percentile 35th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CHCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XRN Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CHCT Moat Profile Scale & Operating Efficiency Moat
REIT - Healthcare Facilities Operator
Competes within the REIT - Healthcare Facilities value chain with $422.8M market capitalization and 28.1% operating margin.
OpEx & R&D Reinvestment 52.7% of Rev ($66M)
90D Engineering Disclosures 0 Published

Investor FAQ XRN vs CHCT Key Questions & Quantitative Answers

As of Nov 17, 2026, Community Healthcare Trust Incorporated (CHCT) is the stronger overall head-to-head candidate over XRN (XRN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). XRN carries a Unified Composite Score of 45.3/100 (HOLD) at $25.79 (N/M Forward P/E, N/A operating margin), whereas CHCT carries 28.1/100 (SELL) at $14.52 (37.3x Forward P/E, 28.1% operating margin). Composite vs. Pillar Nuance: While XRN currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. CHCT 28.1/100 SELL), CHCT captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (28.1% vs. N/A operating margin) and revenue trajectory (+4.4% vs. N/A YoY). Technical & Structure Timing Caution: XRN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.5); meanwhile CHCT trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 58.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CHCT leads the Growth & Scale pillar: XRN posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CHCT at +4.4% YoY revenue growth and +179.9% YoY earnings growth on $126M TTM revenue (80.8% gross margin, 28.1% operating margin). On trailing 12-month operating scale, XRN generates N/A in USD-normalized revenue versus $126M for CHCT. In operating R&D and SG&A reinvestment, XRN deploys N/A (0 90-day corporate R&D disclosures) versus 52.7% of Rev ($66M) (0 disclosures) for CHCT.

CHCT screens cheaper on headline valuation multiples. XRN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CHCT trades at 37.3x Forward P/E, 20.1x Trailing P/E, N/M PEG, and 3.4x EV/Revenue (63.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XRN (N/A ROE) versus CHCT (5.3% ROE) capital efficiency.

In options market volatility and institutional positioning, XRN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.50β · 47% Vol realized risk). By comparison, CHCT carries 38.6% implied volatility (35th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 45% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.